PDE4A and chronic obstructive pulmonary disease: More importantly, many PDE4 inhibitors in development are efficacious in animal models of various inflammatory disorders, such as asthma, COPD, psoriasis, inflammatory bowel diseases, and rheumatoid arthritis (3, 6, 7), as well as in clinical trials for asthma and COPD (8-10).